Latest Cost Management News

Corella Resources has successfully raised over $1 million through a Rights Issue and Placement, positioning itself to advance exploration and development at its Tampu Project and other tenements.

Income Asset Management Group Limited delivered its strongest quarter ever in Q4 FY2025, reporting record revenue and robust growth in funds under advice alongside positive operating cash flow.

Farm Pride Foods reports a 27% production surge supported by avian influenza recovery and secures $27.6 million financing for facility upgrades and expansion.

Epx Limited reports sustained operational improvement with four consecutive quarters of positive cash inflows and a 26% increase in customer receipts for the June 2025 quarter.

Step One Clothing reports modest revenue growth for FY25 despite a dip in earnings before interest and tax, highlighting ongoing consumer caution and strategic marketing restraint.

Fenix Resources has marked a milestone quarter with the start of mining at Beebyn-W11, joining Iron Ridge and Shine mines to push production towards 4 million tonnes annually in 2025. The company also reported record shipments and improved cost efficiency, underpinning its growth strategy in Western Australia's Mid-West.

Fortescue Metals Group delivered record iron ore shipments in FY25 alongside a rare cost decline, while recalibrating its green energy ambitions and maintaining a strong financial position.

ReadCloud Limited reported a robust 35% increase in cash receipts for the June quarter, driven by strong growth in its VET-in-Schools segment and disciplined cost management. The company forecasts positive underlying EBITDA and operating cash flow for FY25, positioning itself for accelerated growth in 2026.

Highfield Resources has entered a significant non-binding agreement with China’s Qinghai Salt Lake Industry for a US$300 million equity injection, aiming to fast-track its Muga potash mine development and expand its global footprint.

Bod Science reports a solid net cash inflow of $858,000 in Q4 FY2025, driven by R&D incentives and Biortica funding, while awaiting shareholder approval to complete a key acquisition.

InhaleRx Limited has secured key ethics approvals and initiated manufacturing for its inhaled drug candidates targeting breakthrough cancer pain and panic disorder, supported by a $38.5 million funding facility to accelerate development.

Credit Clear Limited has outperformed its FY25 financial guidance with a 76% rise in underlying EBITDA and secured exclusive digital debt recovery contracts with leading insurers, setting a robust stage for FY26 growth.